Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 1997

View Archived Issues

Improved fibrinogen antagonists from DuPont Merck

Excitatory amino acid receptor ligands from Schering AG

FPTase inhibitors in early development at Merck & Co.

Hoechst reports new Na+/K+-exchange inhibitors

Therapeutically active PTH derivatives reported by Takeda

NK1 antagonists from Takeda

Antithrombotics described by Terumo

Sumitomo claims antiplatelet agents

Kotobuki discloses muscarinic antagonists

Sagami reports novel antitumor agents

Combination therapy for HCV

5-LO inhibitor not effective in psoriasis

Peptide Therapeutics and Medeva collaborate on vaccine development

Development of Hepagene progresses

Medeva begins full development of ADHD Rx

New approach to arrhythmia using novel SKB compound

Pharmos allowed patent for tamoxifen analogues

Allelix/Aurora enter drug discovery collaboration

Company Profile: Essential Nutrition

Allelix and Pharm-Eco form joint venture

Spotlight on CCK-B antagonists for anxiety

Promising findings reported for senescence genes

FDA to review generic immunosuppressant

Promising new Sawai antiulcer drug shows excellent results in rats

Research shows antibodies associated with resistance to AIDS

BMS/Xenova collaborate on drug discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...